The treatment of advanced gastric cancer: New findings on the activity of the taxanes

Oncologist

Volumn 9, Issue SUPPL. 2, 2004, Pages 9-15

  Van Cutsem, Eric ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Advanced gastric cancer; Docetaxel; Gastric cancer; Paclitaxel; Taxanes

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CISPLATIN; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MITOMYCIN; OXALIPLATIN; PACLITAXEL; TAXANE DERIVATIVE; UFT;

ADVANCED CANCER; ALOPECIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; HUMAN; INFECTION; LETHARGY; METASTASIS; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEUROLOGIC DISEASE; NEUROSENSORY DISEASE; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; SOMATOSENSORY CORTEX; STOMACH CANCER; STOMATITIS; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PACLITAXEL; PROGNOSIS; RISK ASSESSMENT; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 2942558417     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.9-suppl_2-9     Document Type: Conference Paper

References (43)

1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001;2:533-543.
2. Jemal A, Thomas A, Murray T et al. Cancer statistics, 2002. CA Cancer J Clin 2002;52:23-47.
3. Blot WJ, Devesa SS, Kneller RW et al. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991;265:1287-1289.
4. Hohenberger P, Gretschel S. Gastric cancer. Lancet 2003;362:305-315.
5. Pyrhonen S, Kuitunen T, Nyandoto P et al. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995;71:587-591.
6. Murad AM, Santiago FF, Petroianu A et al. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993;72:37-41.
7. Schipper DL, Wagener DJ. Chemotherapy of gastric cancer. Anticancer Drugs 1996;7:137-149.
8. Glimelius B, Ekstrom K, Hoffman K et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997;8:163-168.
9. Murad AM, Petroianu A, Guimaraes RC et al. Phase II trial of the combination of paclitaxel and 5-fluorouracil in the treatment of advanced gastric cancer: a novel, safe, and effective regimen. Am J Clin Oncol 1999;22:580-586.
10. Ridwelski K, Gebauer T, Fahlke J et al. Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer. Ann Oncol 2001;12:47-51.
11. Ajani JA, Baker J, Pisters PW et al. Irinotecan plus cisplatin in advanced gastric or gastroesophageal junction carcinoma. Oncology (Huntingt) 2001;15(suppl 5):52-54.
12. Louvet C, André T, Tigaud JM et al. Phase II trial of oxaliplatin (OXA) in combination with 5-FU and folinic acid (FA)-FOL-FOX6 regimen-as first-line treatment for advanced or metastatic gastric cancer (A/MGC) patients. Proc Am Soc Clin Oncol 2000;19:265a.
13. Chollet P, Schoffski P, Weigang-Kohler K et al. Phase II trial with S-1 in chemotherapy-naïve patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG). Eur J Cancer 2003;39:1264-1270.
14. Koizumi W, Saigenji K, Ujiie S et al. A pilot phase II study of capecitabine in advanced or recurrent gastric cancer. Oncology 2003;64:232-236.
15. Kopp R, Rothbauer E, Ruge M et al. Clinical implications of the EGF receptor/ligand system for tumor progression and survival in gastrointestinal carcinomas: evidence for new therapeutic options. Recent Results Cancer Res 2003;162:115-132.
16. Crown J, O'Leary M. The taxanes: an update. Lancet 2000;355:1176-1178.
17. Liu B, Staren ED, Iwamura T et al. Mechanisms of taxotere-related drug resistance in pancreatic carcinoma. J Surg Res 2001;99:179-186.
18. Reinecke P, Schmitz M, Schneider EM et al. Multidrug resistance phenotype and paclitaxel (Taxol) sensitivity in human renal carcinoma cell lines of different histologic types. Cancer Invest 2000;18:614-625.
19. Ajani JA, Fairweather J, Dumas P et al. Phase II study of Taxol in patients with advanced gastric carcinoma. Cancer J Sci Am 1998;4:269-274.
20. Mai M, Sakata Y, Kanamaru R et al. [A late phase II clinical study of RP56976 (docetaxel) in patients with advanced or recurrent gastric cancer: a cooperative study group trial (group B)]. Gan To Kagaku Ryoho 1999;26:487-496. Japanese.
21. Graziano F, Catalano V, Baldelli AM et al. A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer. Ann Oncol 2000;11:1263-1266.
22. Ohtsu A, Boku N, Tamura F et al. An early phase II study of a 3-hour infusion of paclitaxel for advanced gastric cancer. Am J Clin Oncol 1998;21:416-419.
23. 2 is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial. Jpn J Clin Oncol 2002;32:248-254.
24. Vanhoefer U, Harstrick A, Wilke H et al. Schedule-dependent antagonism of paclitaxel and cisplatin in human gastric and ovarian carcinoma cell lines in vitro. Eur J Cancer 1995;31A:92-97.
25. Kim YH, Shin SW, Kim BS et al. Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma. Cancer 1999;85:295-301.
26. Kollmannsberger C, Quietzsch D, Haag C et al. A phase II study of paclitaxel, weekly, 24-hour continuous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer. Br J Cancer 2000;83:458-462.
27. Ryoo B, Kim T, Choi S et al. A phase II trial of paclitaxel (T) and carboplatin (C) for advanced gastric cancer refractory to 5-fluorouracil (F) and cisplatin/heptaplin (P). Proc Am Soc Clin Oncol 2001;20:28b.
28. Honecker F, Kollmannsberger C, Quietzsch D et al. Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer. Anticancer Drugs 2002;13:497-503.
29. Gadgeel SM, Shields AF, Heilbrun LK et al. Phase II study of paclitaxel and carboplatin in patients with advanced gastric cancer. Am J Clin Oncol 2003;26:37-41.
30. Roth AD, Maibach R, Martinelli G et al. Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO). Ann Oncol 2000;11:301-306.
31. Kettner E, Ridwelski K, Keilholtz U et al. Docetaxel and cisplatin combination therapy for advanced gastric cancer: results of two phase II studies. Proc Am Soc Clin Oncol 2001;20:163.
32. Constenla M, Garcia-Arroyo R, Lorenzo I et al. Docetaxel, 5-fluorouracil, and leucovorin as treatment for advanced gastric cancer: results of a phase II study. Gastric Cancer 2002;5:142-147.
33. Hawkins R, Cunningham D, Soerbye H et al. Randomized phase II trial of docetaxel plus irinotecan versus docetaxel plus 5-fluorouracil (5FU) in patients with untreated advanced gastric adenocarcinoma (AGAC). Proc Am Soc Clin Oncol 2003;22:257.
34. Ajani JA, Fodor M, Van Cutsem E et al. Multinational randomized phase II trial of docetaxel (T) and cisplatin (C) with or without 5-fluorouracil (FU) in patients (pts) with advanced gastric or GE junction adenocarcinoma (AGC-AGEJC). Proc Am Soc Clin Oncol 2000;19:247a.
35. Roth AD, Ajani J. Docetaxel-based chemotherapy in the treatment of gastric cancer. Ann Oncol 2003;14(suppl 2):ii41-ii44.
36. Van Cutsem E, Ajani J, Tjuladin S et al. Docetaxel (T) in combination with cisplatin (C) with or without 5-fluorouracil (F) in patients (pts) with advanced gastric or GE junction adenocarcinoma (AGC): preliminary results. Ann Oncol 2000;11 (suppl 4):63.
37. Ajani JA, Van Cutsem E, Moiseyenko S et al. Docetaxel (D), cisplatin, 5-fluorouracil compare to cisplatin (C) and 5-fluorouracil (F) for chemotherapy-naïve patients with metastatic or locally recurrent, unresectable gastric carcinoma (MGC): interim results of a randomized phase III trial (V325). Proc Am Soc Clin Oncol 2003;22:249.
38. Van Cutsem E, Moiseyenko V, Tjulandin S et al. Docetaxel (D), cisplatin (C), 5-fluorouracil (F) compared to cisplatin (C) and 5-fluorouracil (F) for chemotherapy-naïve patients with metastatic or locally recurrent, unresectable gastric carcinoma (MGC): interim results of a randomised phase III trial (V325). Eur J Cancer 2003;1:5.
39. Webb A, Cunningham D, Scarffe JH et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997;15:261-267.
40. Ohtsu A, Shimada Y, Shirao K et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: the Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 2003;21:54-59.
41. Vanhoefer U, Rougier P, Wilke H et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 2000;18:2648-2657.
42. Pozzo C, Bugat R, Peschel C et al. Irinotecan in combination with CDDP or 5-FU and folinic acid is active in patients with advanced gastric or gastro-esophageal junction adenocarcinoma: final results of a randomized phase II study. Proc Am Soc Clin Oncol 2001;20:134a.
43. Sumpter K, Harper-Wynne C, Cunningham D et al. Randomized, multicenter phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced esophagogastric cancer: confirmation of dose escalation. Proc Am Soc Clin Oncol 2003;22:257.